The XTEND-CIU study: Long-term use of omalizumab in chronic idiopathic urticaria - 14/12/17
Doi : 10.1016/j.jaci.2017.10.018
Marcus Maurer, MD a 
, Allen Kaplan, MD b, Karin Rosén, MD, PhD c, Michael Holden, MD, MS c, Ahmar Iqbal, MD c, Benjamin L. Trzaskoma, MS c, Ming Yang, PhD c, Thomas B. Casale, MD d
, Allen Kaplan, MD b, Karin Rosén, MD, PhD c, Michael Holden, MD, MS c, Ahmar Iqbal, MD c, Benjamin L. Trzaskoma, MS c, Ming Yang, PhD c, Thomas B. Casale, MD d a Department of Dermatology and Allergy, Allergie-Centrum-Charité, Charité–Universitätsmedizin Berlin, Berlin, Germany
b Medical University of South Carolina, Charleston, SC
c Genentech, Inc, South San Francisco, Calif
d University of South Florida, Tampa, Fla
Sous presse. Épreuves corrigées par l'auteur.
Disponible en ligne depuis le Thursday 14 December 2017
Cet article a été publié dans un numéro de la revue, cliquez ici pour y accéder
Cet article a été publié dans un numéro de la revue, cliquez ici pour y accéder
| This study was funded by Genentech, Inc, South San Francisco, Calif. Third-party writing assistance was provided by Linda Wagner, PharmD, of Envision Pharma Group (Excel Scientific Solutions, Inc), and funded by Genentech, Inc, and Novartis Pharmaceuticals Corporation. |
|
| Disclosure of potential conflict of interest: M. Maurer has consultant arrangements with FAES, Genentech, Inc, Novartis, and Uriach; has received honoraria for lectures from Novartis; has received travel support from Genentech, Inc; has received fees for participation in review activities from Genentech, Inc; has board memberships with Genentech, Inc, Novartis, and Uriach; has received research funding from Novartis to his department; and has received grants from FAES, Novartis, and Uriach. A. Kaplan has performed adjudications of adverse events for Genentech, Inc, Novartis, and Sanofi-Aventis; served on an ad hoc advisory board for CSL Behring; and has consultant arrangements with Genentech, Inc. K. Rosén was employed by and received stock/stock options from Genentech, Inc during the conduct of this study. M. Holden and B. L. Trzaskoma are employed by and receive stock/stock options from Genentech, Inc. A. Iqbal is currently employed by Genentech, Inc, has been employed previously by Pfizer and GlaxoSmithKline, and has received stock/stock options from Genentech, Pfizer, and GlaxoSmithKline. M. Yang is employed by Genentech, Inc. T. B. Casale's university employer has received grants and consulting fees from Genentech, Inc and Novartis. T. B. Casale has received grants from Genentech, Inc and Novartis; has consultant arrangements with Genentech, Inc; and is the Executive Vice President of the American Academy of Allergy, Asthma & Immunology. |
© 2017
American Academy of Allergy, Asthma & Immunology. Publié par Elsevier Masson SAS. Tous droits réservés.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?